NOTVQ Inotiv (NOTVQ) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-commercial physical & biological research · CIK 0000720154
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter
Inotiv insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Inotiv, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
Revenue
+4.5% year over year
more than 52% of Pharma & Biotech
Margin
-13.4% net margin
more than 62% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NOTVQ
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns NOTVQ: institutional holders (13F)
13F holdings, latest reported quarter
28,250,000 sh
$847.5K
22,000 sh
$3.1K
11,608 sh
$116
$103
Congress trades in NOTVQ
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NOTVQ planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NOTVQ mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Lazard Enhanced Opportunities Portfolio
$13.3K position · as of 2026-06-30
0.0%
Franklin Alternative Strategies Fund
$29.1K position · as of 2026-05-29
0.0%
JNL Multi-Manager Alternative Fund
$20.8K position · as of 2026-06-30
0.0%
Franklin Alternative Strategies Fund
$4.9K position · as of 2026-05-29
0.0%
Fidelity Extended Market Index Fund
$84.8K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$16.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Robert W. Leasure, Jr.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.7M
$1.4M
$479.2K
-94%
n/a
2023
$4.5M
-$2.5M
$519.7K
-89%
n/a
2022
$10.8M
$8.1M
$4.3M
-42%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NOTVQ financials
Revenue growth
+4.5%
XBRL, annual
Net margin
-13.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$507.4M
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM NOTVQ
| FY Sep 2025 | $513.0M |
| FY Sep 2024 | $490.7M |
| FY Sep 2023 | $572.4M |
| FY Sep 2022 | $547.7M |
| FY Sep 2021 | $89.6M |
| Mar 2026 | $117.7M |
| Dec 2025 | $120.9M |
| Sep 2025 | $138.1M |
| Jun 2025 | $130.7M |
| Mar 2025 | $124.3M |
| Dec 2024 | $119.9M |
| Sep 2024 | $130.4M |
| Jun 2024 | $105.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-17.1%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM NOTVQ
| FY Sep 2025 | -13.4% |
| FY Sep 2024 | -22.1% |
| FY Sep 2023 | -18.4% |
| FY Sep 2022 | -61.5% |
| FY Sep 2021 | +12.2% |
| Mar 2026 | -27.6% |
| Dec 2025 | -23.5% |
| Sep 2025 | -6.2% |
| Jun 2025 | -13.5% |
| Mar 2025 | -12.0% |
| Dec 2024 | -23.0% |
| Sep 2024 | -14.5% |
| Jun 2024 | -24.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$13.6M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM NOTVQ
| FY Sep 2025 | -$27.1M |
| FY Sep 2024 | -$29.1M |
| FY Sep 2023 | $380.0K |
| FY Sep 2022 | -$41.5M |
| FY Sep 2021 | n/a |
| Mar 2026 | -$3.2M |
| Dec 2025 | -$10.6M |
| Sep 2025 | $11.6M |
| Jun 2025 | -$11.5M |
| Mar 2025 | -$18.3M |
| Dec 2024 | -$9.0M |
| Sep 2024 | -$7.7M |
| Jun 2024 | -$19.2M |
At each fiscal year end
Single quarter
Debt to equity
5.32x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity NOTVQ
| FY Sep 2025 | 2.96x |
| FY Sep 2024 | 2.31x |
| FY Sep 2023 | 1.40x |
| FY Sep 2022 | 0.94x |
| FY Sep 2021 | 1.56x |
| Mar 2026 | 5.32x |
| Dec 2025 | 3.72x |
| Sep 2025 | 2.96x |
| Jun 2025 | 2.76x |
| Mar 2025 | 2.53x |
| Dec 2024 | 2.33x |
| Sep 2024 | 2.31x |
| Jun 2024 | 2.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.00x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt NOTVQ
| FY Sep 2025 | -0.03x |
| FY Sep 2024 | -0.02x |
| FY Sep 2023 | 0.07x |
| FY Sep 2022 | -0.02x |
| FY Sep 2021 | 0.07x |
| Mar 2026 | 0.00x |
| Dec 2025 | -0.03x |
| Sep 2025 | -0.03x |
| Jun 2025 | -0.07x |
| Mar 2025 | -0.09x |
| Dec 2024 | -0.01x |
| Sep 2024 | -0.02x |
| Jun 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-74.1%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity NOTVQ
| FY Sep 2025 | -44.8% |
| FY Sep 2024 | -49.3% |
| FY Sep 2023 | -33.4% |
| FY Sep 2022 | -144.8% |
| FY Sep 2021 | +19.3% |
| Mar 2026 | -74.1% |
| Dec 2025 | -49.8% |
| Sep 2025 | -44.8% |
| Jun 2025 | -48.5% |
| Mar 2025 | -48.0% |
| Dec 2024 | -56.9% |
| Sep 2024 | -49.3% |
| Jun 2024 | -43.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-11.8%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets NOTVQ
| FY Sep 2025 | -8.8% |
| FY Sep 2024 | -13.2% |
| FY Sep 2023 | -11.6% |
| FY Sep 2022 | -52.5% |
| FY Sep 2021 | +5.7% |
| Mar 2026 | -11.8% |
| Dec 2025 | -9.2% |
| Sep 2025 | -8.8% |
| Jun 2025 | -10.3% |
| Mar 2025 | -11.1% |
| Dec 2024 | -15.0% |
| Sep 2024 | -13.2% |
| Jun 2024 | -12.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital NOTVQ
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.8%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed NOTVQ
| FY Sep 2025 | -7.1% |
| FY Sep 2024 | -12.5% |
| FY Sep 2023 | -10.7% |
| FY Sep 2022 | -49.4% |
| FY Sep 2021 | -3.8% |
| Mar 2026 | -11.8% |
| Dec 2025 | -7.4% |
| Sep 2025 | -7.1% |
| Jun 2025 | -8.2% |
| Mar 2025 | -10.8% |
| Dec 2024 | -13.3% |
| Sep 2024 | -12.5% |
| Jun 2024 | -13.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NOTVQ
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$395.6M
market value at close 2026-07-27 on 2026-04-16 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value NOTVQ
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3,515%
TTM free cash flow over market value at close 2026-07-27
FCF yield NOTVQ
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NOTVQ
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-07-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $513.0M | $490.7M | $572.4M | $547.7M |
| Operating income | -$30.9M | -$86.4M | -$81.5M | -$263.5M |
| Net income | -$68.6M | -$108.4M | -$105.1M | -$337.0M |
| EPS (diluted) | -2.11 | -4.19 | -4.10 | -13.84 |
| Operating cash flow | -$10.5M | -$6.8M | $27.9M | -$5.2M |
| Cash | $21.7M | $21.4M | $35.5M | $18.5M |
| Long-term debt | $0 | $389.8M | $369.8M | $330.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
NOTVQ Stock Sonar score 5/7 axes
Find similar shapesCompareNOTVQ ranks highest on profitability (64th percentile) and growth (52nd), and lowest on institutional and government (11th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
